Special Edition: What's Next—Cardiovascular Risk in CKD—The Overlooked Burden

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD.

This special episode is sponsored with support from Bayer.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

-Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

-Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine.

Selected references:

-Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260

-Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229

-Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446

-Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121